homocysteine and Parkinson Disease

homocysteine has been researched along with Parkinson Disease in 151 studies

Research

Studies (151)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (3.31)	18.2507
2000's	68 (45.03)	29.6817
2010's	52 (34.44)	24.3611
2020's	26 (17.22)	2.80

Authors

Authors	Studies
Adarmes-Gómez, A; Aramburu, IG; Arroyo, SE; Ávila, A; Barberá, MA; Bejr-Kasem, H; Campolongo, A; Carrillo, F; Ceberio, JI; de Deus Fonticoba, T; de Fábregues-Boixar, O; Foraster, AC; Grothe, MJ; Horta-Barba, A; Jesús, S; Kulisevsky, J; Labrador-Espinosa, MA; Lora, FR; Martínez, JR; Martínez-Castrillo, JC; Martínez-Horta, S; Martínez-Martín, P; Mir, P; Morlans, MP; Padilla, FC; Pascual-Sedano, B; Pastor, P; Puig-Davi, A; Sampedro, F; Santos-García, D; Vara, JH; Vila, BS	1
Christine, CW; Green, R	1
Bjørk, MH; Bjørke-Monsen, AL; Storstein, A; Tysnes, OB; Ueland, PM	1
Bai, Y; Gu, R; Jiang, X; Jiang, Y; Pan, Y; Shen, B; Wang, Y; Yan, J; Zhang, L; Zhong, M; Zhu, J; Zhu, S	1
Chen, J; Cheng, XY; Gu, HY; Jin, H; Li, K; Liu, CF; Liu, MH; Mao, CJ; Xiong, YT; Zhang, JR	1
Müller, T; Schlegel, E; Thiede, HM; Zingler, S	1
Kulisevsky, J; Martínez-Horta, S; Sampedro, F	1
Boleková, V; Gmitterová, K; Košutzká, Z; Matejička, P; Minár, M; Valkovič, P	1
Adarmes-Gómez, AD; Bonilla-Toribio, M; Buiza-Rueda, D; Gómez-Garre, P; Jesús, S; Jimenez-Jaraba, MV; Macías-García, D; Martín-Rodríguez, JF; Mir, P; Muñoz-Delgado, L; Periñán, MT	1
Majdal, H; Natheer, M; Taher, Y	1
Ahlskog, JE	1
Bhidayasiri, R; Garcia-Ruiz, P; Müller, T; Odin, P; Phokaewvarangkul, O; Riederer, P	1
Gou, M; Guo, X; Liu, Y	1
Gao, F; Gao, L; Miao, J; Yang, Y	1
Kim, MS; Park, DG; Shin, IJ; Yoon, JH	1
Dong, B; Wu, R	1
Chen, L; Gu, C; Li, D; Li, J; Zhu, M; Zhu, X	1
Cao, P; Chan, L; Chan, P; Chang, Z; Chao, Y; Chen, Z; Deng, B; Lyu, Q; Pan, Y; Que, R; Tan, EK; Wang, Q; Wang, T; Wang, Y; Xu, L; Yang, W; Yenari, MA; Yuan, F; Zhu, S	1
Chen, G; Fan, X; Jin, Y; Li, H; Ma, X; Qi, G; Zhang, L	1
Baik, JS; Lee, JJ	1
Bedarf, J; Bidkhori, G; Ehrlich, SD; Hildebrand, F; Le Chatelier, E; Lee, S; Mardinoglu, A; Proctor, G; Rosario, D; Shoaie, S; Uhlen, M; Wüllner, U	1
Anamnart, C; Kitjarak, R	1
de Almeida, AG; Finsterer, J; Rodrigues, AM; Scorza, CA; Scorza, FA	1
Gan, Y; Jiang, H; Li, H; Liu, M; Yao, S; Yin, G; Yin, P; Yu, T; Zhang, Y	1
Chen, XF; Ding, CW; Fu, XY; Liu, CF; Mao, CJ; Mao, P; Sheng, YJ; Song, X; Wang, CS; Yang, M; Zhang, Y; Zhang, YC	1
Guo, N; Liu, X; Tian, D; Zhang, C; Zhang, J; Zhao, Y; Zhu, R	1
Chen, L; Guo, Y; Hu, X; Huang, ZN; Liao, XX; Wu, LL; Xian, WB; Zhang, XS; Zhuang, XD	1
Kang, K; Ko, PW; Lee, HW; Park, D; Park, JS	1
Andréasson, M; Brodin, L; Laffita-Mesa, JM; Svenningsson, P	1
Cholerton, B; Chung, KA; Edwards, K; Hu, SC; Leverenz, JB; Licking, N; Montine, TJ; Murchison, C; Peterson-Hiller, AL; Quinn, JF; Zabetian, CP	1
Alpert, JS	1
Auinger, P; Christine, CW; Green, R; Joslin, A; Yelpaala, Y	1
Čierny, D; Grofik, M; Kurča, E; Michalik, J; Nosáľ, V; Sivák, Š; Tatarková, Z; Turčanová Koprušáková, M	1
Dong, Q; Fang, L; Li, J; Liao, J; Lu, T; Lu, Z; Peng, F; Qin, F; Qiu, W; Sun, X; Xu, X	1
Burn, DJ; Duncan, GW; Johnston, F; Khoo, TK; Lawson, RA; Sleeman, I; Yarnall, AJ	1
Dong, ZF; Huang, JY; Liu, CF; Pan, PL; Shen, Y; Xu, G	1
Jadavji, NM; Murray, LK	1
Hu, LF; Hu, XW; Li, D; Liu, CF; Qin, SM	1
Li, Q; Liu, W; Sun, YN; Wang, Y; Yang, JF; Zhang, BS; Zhang, W; Zhao, P	1
Abbruzzese, G; Bandettini di Poggio, M; Barone, P; Bonuccelli, U; Borelli, P; Ceravolo, R; Contu, P; Cossu, G; Frosini, D; Iodice, R; Lopiano, L; Manca, D; Manganelli, F; Marchese, R; Melis, M; Mereu, A; Merola, A; Nicoletti, V; Paribello, A; Picillo, M; Santoro, L; Zibetti, M	1
Antonini, A; Calandrella, D; Cantello, R; Coletti Moja, M; Comi, C; Dal Fante, M; Lacerenza, M; Mancini, F; Manfredi, L; Oggioni, GD; Pacchetti, C; Riboldazzi, G; Tunesi, S	1
Ludwichowska, A; Szabat, K; Szadejko, K; Sławek, J	1
Camicioli, R; Emery, D; Gee, M; Sabino, J; Sapkota, S	1
Borgohain, R; Kumudini, N; Kutala, VK; Mridula, R; Naushad, SM; Uma, A	1
Azhdari-Zarmehri, H; Dargahi, T; Faraj, A; Fraidouni, N; Haghdoost-Yazdi, H; Sarookhani, M; Yaghoubidoust, MH	1
Hong, JM; Lee, JS; Lee, PH; Yong, SW; Yoon, JH	1
Choo, YM; Kim, HJ; Lim, SY; Mahamad, UA; Yap, AC	1
He, ZY; Liu, HN; Liu, X; Zhu, RX; Zhu, Y	1
Chen, WW; Cheng, X; Huang, WJ; Sun, HQ; Xie, ZY; Zhang, QS; Zhang, X	1
Cakmak, S; Cumhur Cure, M; Cure, E; Kirbas, A; Kirbas, S; Tufekci, A; Yazici, T	1
Cao, LD; Guo, G; Wu, QY; Xu, S	1
Bhidayasiri, R; Boonla, C; Chotipanich, C; Dissayabutra, T; Joutsa, J; Kaewwilai, L; Muensri, S; Rinne, J; Tosukhowong, P	1
Comoglu, SS; Guven, H; Kocer, B	1
Bhattacharjee, N; Borah, A	1
Feng, H; Peng, S; Xiao, J; Xie, Y; Zhang, J	1
Herrman, L; Kinkel, M; Muhlack, S; Müller, T	1
Barone, P; Burn, DJ; Hsu, C; Lane, RM; Poewe, W; van Laar, T	1
Brown, MS; Furtado, S; Suchowersky, O; Toth, C; Zochodne, D	1
Bouchard, TP; Camicioli, RM; Somerville, MJ	1
Hlustik, P; Kanovsky, P; Langova, K; Nevrly, M; Vranova, H	2
Barchak, AG; Busanello, EN; Camargo, D; Carrion, MJ; da Costa, JC; Dalbem, A; de Mello Rieder, CR; de Sousa Miguel, SR; dos Santos, EF; Miglioranza, A; Rosa, C; Saute, J; Vargas, CR; Wajner, M; Zanatta, A	1
Abruzzese, G; Antonini, A; Bonuccelli, U; Canesi, M; Cristina, S; Defazio, G; dell'Aquila, C; Lamberti, P; Livrea, P; Logroscino, G; Marchese, R; Pacchetti, C; Zagaglia, R; Zoccolella, S	1
Kuhn, W; Müller, T	3
Bescos, E; Clavero, P; García-Garcia, D; Irigoien, J; Irurzun, C; Kulisevsky, J; Lage, PM; Lamet, I; Matsubara, JM; Obeso, JA; Pagonabarraga, J; Pérez-Tur, J; Rodriguez-Oroz, MC; Samaranch, L; Sanchez-Mut, J; Toledo, JB	1
Muhlack, S; Müller, T	2
Dillmann, U; Fassbender, K; Herrmann, W; Kostopoulos, P; Obeid, R; Schadt, A	1
Chiang, TR; Ho, CS; Hu, CJ; Hung, YL; Sheu, JJ; Tseng, IJ; Yeh, CY; Yu, JM; Yuan, RY	1
Barone, P; De Bonis, ML; Galletti, P; Ingrosso, D; Longo, K; Pellecchia, MT; Russo, A; Salvatore, A; Tedeschi, G; Tessitore, A; Zappia, V	1
Chun, S; Chung, SJ; Kim, BJ; Kim, GS; Kim, MJ; Kim, SR; Koh, JM; Lee, MC; Lee, SH; Ryu, JS	1
Litvinenko, IV; Mogil'naya, VI; Odinak, MM; Perstnev, SV	1
Belcastro, V; Calabresi, P; Castrioto, A; Gorgone, G; Ientile, R; Menichetti, C; Pierguidi, L; Pisani, F; Rossi, A; Tambasco, N	1
Abe, T; Isobe, C; Terayama, Y	1
Antonini, A; Bareggi, SR; Bondiolotti, G; Natuzzi, F	1
Bötzel, K; Giese, A; Levin, J; Lorenzl, S; Vogeser, M	1
Iliceto, G; Lamberti, P; Lamberti, SV; Logroscino, G; Santamato, A; Zoccolella, S	1
Sui, R; Zhang, L	1
Bengel, G; Ebersbach, G; Ehret, R; Jugel, C; Klostermann, F; Muhlack, S; Müller, T	1
Müller, T	2
Muhlack, S; Müller, T; Woitalla, D	1
Bian, L; Chen, X; Jiang, Y; Long, L; Wang, Q; Xu, Y; Yan, J; Yang, L; Zhang, L; Zhu, C	1
Garlipp, CR; Gobbi, LT; Gobbi, S; Nascimento, CM; Santos, RF; Stella, F	1
Belcastro, V; Caccamo, D; Calabresi, P; Currò, M; Ferlazzo, N; Gorgone, G; Ientile, R; Parisi, G; Parnetti, L; Pisani, F; Rossi, A; Tambasco, N	1
Bandurski, T; Białecka, M; Budrewicz, S; Droździk, M; Dubaniewicz, M; Gorzkowska, A; Gołąb-Janowska, M; Honczarenko, K; Koziorowska-Gawron, E; Kurzawski, M; Mak, M; Robowski, P; Roszmann, A; Sitek, EJ; Sławek, J	1
Białecka, M; Budrewicz, S; Droździk, M; Gorzkowska, A; Gołąb-Janowska, M; Honczarenko, K; Jarosz, M; Koziorowska-Gawron, E; Kurzawski, M; Mak, M; Robowski, P; Roszmann, A; Sitek, EJ; Sławek, J	1
Ahn, YH; Lee, PH; Paik, MJ; Park, HJ; Shin, JY; Sohn, YH	1
Cosar, A; Ozcan, O	1
Boldyrev, A; Bryushkova, E; Mashkina, A; Vladychenskaya, E	1
Artner-Dworzak, E; Frick, B; Fuchs, D; Laich, A; Leblhuber, F; Widner, B	1
Miller, JW	1
Diaz-Arrastia, R; Frol, AB; Rogers, JD; Sanchez-Saffon, A	1
Mattson, MP; Shea, TB	1
Mattson, MP	1
Fuchs, D; Leblhuber, F; Neurauter, G	1
Kowa, H; Kusumi, M; Nakashima, K; Nakaso, K; Sasaki, K; Takeshima, T; Ueda, K; Yasui, K; Yoshimoto, Y	1
Feldman, RG; Miller, JW; Nadeau, MR; Selhub, J; Thomas, CA; Wolf, PA	1
Kowa, H; Nakashima, K; Nakaso, K; Takeshima, T; Yasui, K	2
Coimbra, CG; Junqueira, VB	1
Lökk, J	1
Di Rocco, A; Werner, P	1
Fuchs, D; Leblhuber, F; Schroecksnadel, K	1
Sachdev, P	1
Diaz-Arrastia, R; O'Suilleabhain, P	1
Kuhn, W; Müller, T; Renger, K	1
Bottiglieri, T; Dewey, RB; Diaz-Arrastia, R; Hernandez, C; Lacritz, L; O'Suilleabhain, PE; Sung, V	1
Brosnan, JT; Brosnan, ME; Jacobs, RL; Stead, LM	1
Ascherio, A; Chen, H; Hernán, MA; Logroscino, G; Schwarzschild, MA; Willett, WC; Zhang, SM	1
Lang, AE; Postuma, RB	1
Armenise, E; de Mari, M; Fraddosio, A; Iliceto, G; Lamberti, P; Livrea, P; Zoccolella, S	1
Agnati, LF; Antonelli, F; Cortelli, P; Fuxe, K; Galantucci, M; Genedani, S; Guidolin, D; Rasio, G	1
Hefter, H; Hueber, R; Jost, WH; Leenders, KL; Müller, T; Odin, P; Schwarz, J	1
Armenise, E; de Mari, M; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Mastronardi, R; Zoccolella, S	1
Armenise, E; de Mari, M; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Zoccolella, S	1
Benetin, J; Blazícek, P; Gmitterová, K; Kukumberg, P; Valkovic, P; Valkovicová, L	1
Isobe, C; Murata, T; Sato, C; Terayama, Y	1
Biagio Mercuri, N; De Sarro, G; Ferreri Ibbadu, G; Gallelli, L; Mancuso, F; Siniscalchi, A	1
Bostantjopoulou, S; Frangia, T; Hatzizisi, O; Katsarou, Z; Kazis, A; Kiosseoglou, G; Kyriazis, G; Papazisis, K	1
Armenise, E; de Mari, M; Defazio, G; Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Zoccolella, S	1
Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K	1
Bottiglieri, T; Diaz-Arrastia, R; Greenberg, SM; Growdon, JH; Gurol, ME; Hyman, BT; Irizarry, MC; Locascio, JJ; Raju, S; Tennis, M	1
Bartis, C; Bottiglieri, T; Dewey, RB; Diaz-Arrastia, R; O'Suilleabhain, PE; Oberle, R	1
Dzoljić, E; Kostić, V; Krajinović, M; Mirković, D; Nesić, Z; Novaković, I; Prostran, M; Stojanović, R; Todorović, Z	1
Armenise, E; de Mari, M; Defazio, G; Dell'Aquila, C; Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Zoccolella, S	1
Barcikowska, M; Chodakowska-Zebrowska, M; Czyzewski, K; Lokk, J; Peplonska, B; Religa, D; Stepien, K; Styczynska, M; Winblad, B	1
Camicioli, R; Espay, AJ; Lafontaine, AL; Lang, AE; Martin, WR; Postuma, RB; Ranawaya, R; Suchowersky, O; Zadikoff, C	1
Defazio, G; Lamberti, P; Livrea, P; Martino, D; Zoccolella, S	1
Aydemir, T; Cetin, S; Hanoglu, L; Koldas, M; Meral, H; Ozer, F; Ozturk, O; Seval, H; Yilsen, M	1
Blandini, F; Martignoni, E; Nappi, G; Pacchetti, C; Tassorelli, C; Zangaglia, R	1
Herrmann, W; Lorenzl, S; Obeid, R	1
Armstrong, VW; Bachmann, CG; Guth, N; Happe, S; Helmschmied, K; Paulus, W	1
Belcastro, V; Caccamo, D; Calabresi, P; Currò, M; Di Iorio, W; Gorgone, G; Ientile, R; Menichetti, C; Parisi, G; Parnetti, L; Pisani, F; Rossi, A	1
Lin, JJ; Lin, SZ; Liu, CS; Liu, JT; Yueh, KC	1
Ascherio, A; Chen, H; Fung, TT; Gao, X; Hu, FB; Logroscino, G; Schwarzschild, MA	1
Chippa, MA; Devrajani, BR; Qureshi, AA; Qureshi, GA; Syed, SA	1
Allain, P; Bagheri, H; Cordillet, E; Le Bouil, A; Le Quay, L; Montastruc, JL	1
Ben-Shlomo, Y; Davey-Smith, G; Harmon, DL; Ramsbottom, D; Whitehead, AS	1
Blom, H; Büttner, T; Kretschmer, A; Kuhn, W; Müller, T; Przuntek, H; Roebroek, R; van Oppenraaij, D; Woitalla, D	1
Blom, H; Kuhn, W; Müller, T; Roebroek, R; van Oppenraaij, D	1
Fowler, B; Kuhn, W; Müller, T; Werne, B	1
Brattström, L	1
Hummel, T; Kuhn, W; Müller, T; Woitalla, D	1
Blandini, F; Fancellu, R; Mangiagalli, A; Martignoni, E; Nappi, G; Pacchetti, C; Samuele, A	1
Fowler, B; Hauptmann, B; Kuhn, W; Müller, T; Woitalla, D	1
Cadet, JL; Cutler, RG; Duan, W; Kruman, II; Ladenheim, B; Mattson, MP	1
Fowler, B; Kuhn, W; Müller, T; Woitalla, D	1

Reviews

26 review(s) available for homocysteine and Parkinson Disease

Article	Year
Homocysteine levels, genetic background, and cognitive impairment in Parkinson's disease. Journal of neurology, 2023, Volume: 270, Issue:1 Topics: Case-Control Studies; Cognitive Dysfunction; Folic Acid; Genetic Background; Genotype; Homocysteine; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Parkinson Disease; Vitamin B 12	2023
Levodopa, homocysteine and Parkinson's disease: What's the problem? Parkinsonism & related disorders, 2023, Volume: 109 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Homocysteine; Humans; Levodopa; Parkinson Disease; Vitamin B 12; Vitamin B Complex	2023
Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson's disease: clinical and therapeutic considerations. Journal of neural transmission (Vienna, Austria : 1996), 2023, Volume: 130, Issue:11 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine; Homocysteine; Humans; Levodopa; Parkinson Disease; Vitamin B 12; Vitamins	2023
Features of Plasma Homocysteine, Vitamin B12, and Folate in Parkinson's Disease: An Updated Meta-Analysis. Journal of integrative neuroscience, 2023, Aug-14, Volume: 22, Issue:5 Topics: Cognitive Dysfunction; Folic Acid; Homocysteine; Humans; Parkinson Disease; Vitamin B 12	2023
Plasma homocysteine, folate and vitamin B12 levels in Parkinson's disease in China: A meta-analysis. Clinical neurology and neurosurgery, 2020, Volume: 188 Topics: Case-Control Studies; China; Folic Acid; Homocysteine; Humans; Parkinson Disease; Vitamin B 12	2020
Role of homocysteine in the development and progression of Parkinson's disease. Annals of clinical and translational neurology, 2020, Volume: 7, Issue:11 Topics: Disease Progression; Homocysteine; Humans; Parkinson Disease	2020
The role of one-carbon metabolism and homocysteine in Parkinson's disease onset, pathology and mechanisms. Nutrition research reviews, 2019, Volume: 32, Issue:2 Topics: Animals; Diet; Folic Acid; Genetic Predisposition to Disease; Homocysteine; Humans; Levodopa; Methylation; Methylenetetrahydrofolate Reductase (NADPH2); Nutritional Status; One-Carbon Group Transferases; Parkinson Disease; Polymorphism, Genetic; Vitamin B Complex	2019
Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis. Acta neurologica Scandinavica, 2013, Volume: 128, Issue:2 Topics: Antiparkinson Agents; Databases, Factual; Homocysteine; Humans; Levodopa; Parkinson Disease	2013
[Homocysteine and its role in pathogenesis of Parkinson's disease and other neurodegenerative disorders]. Przeglad lekarski, 2013, Volume: 70, Issue:7 Topics: Catechol O-Methyltransferase Inhibitors; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Vitamin B Complex	2013
Association of MTHFR C677T with total homocysteine plasma levels and susceptibility to Parkinson's disease: a meta-analysis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2015, Volume: 36, Issue:6 Topics: Asian People; China; Genetic Predisposition to Disease; Homocysteine; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Parkinson Disease; Polymorphism, Single Nucleotide; Risk Factors; White People	2015
Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson's disease: A meta-analysis. Neuroscience letters, 2017, 01-01, Volume: 636 Topics: Adult; Aged; Aged, 80 and over; Cognition; Cognition Disorders; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome; Vitamin B 12	2017
Hyperhomocysteinemia in L-dopa treated patients with Parkinson's disease: potential implications in cognitive dysfunction and dementia? Current medicinal chemistry, 2010, Volume: 17, Issue:28 Topics: Antiparkinson Agents; Cognition Disorders; Dementia; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Neurons; Parkinson Disease	2010
Motor complications, levodopa metabolism and progression of Parkinson's disease. Expert opinion on drug metabolism & toxicology, 2011, Volume: 7, Issue:7 Topics: Animals; Arteriosclerosis; Catechol O-Methyltransferase; Disease Progression; Dopamine; Dyskinesias; Enzyme Inhibitors; Free Radicals; Homocysteine; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Synaptic Transmission	2011
Homocysteine, folate deficiency, and Parkinson's disease. Nutrition reviews, 2002, Volume: 60, Issue:12 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Folic Acid Deficiency; Homocysteine; Humans; Hyperhomocysteinemia; Mice; Parkinson Disease; Risk Factors	2002
Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends in neurosciences, 2003, Volume: 26, Issue:3 Topics: Aging; Alzheimer Disease; Animals; Apoptosis; Cell Death; Depressive Disorder; Folic Acid; Homocysteine; Humans; Mental Disorders; Methylation; Neurodegenerative Diseases; Neuronal Plasticity; Neurons; Parkinson Disease; Schizophrenia; Stroke	2003
[Treatment with levodopa can affect latent vitamin B 12 and folic acid deficiency. Patients with Parkinson disease runt the risk of elevated homocysteine levels]. Lakartidningen, 2003, Aug-28, Volume: 100, Issue:35 Topics: Animals; Antiparkinson Agents; Biomarkers; Blood-Brain Barrier; Folic Acid Deficiency; Homocysteine; Humans; Levodopa; Parkinson Disease; Vitamin B 12 Deficiency	2003
[Homocysteine and neuropsychiatric disorders]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2004, Volume: 26, Issue:1 Topics: Alzheimer Disease; Dementia, Vascular; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Mental Disorders; Parkinson Disease; Risk Factors; Stroke; Vitamin B 12; Vitamin B 6	2004
Methylation demand: a key determinant of homocysteine metabolism. Acta biochimica Polonica, 2004, Volume: 51, Issue:2 Topics: Animals; Creatine; Guanidinoacetate N-Methyltransferase; Homocysteine; Humans; Levodopa; Methylation; Methyltransferases; Models, Biological; Models, Chemical; Parkinson Disease; Phosphatidylcholines; Phosphatidylethanolamine N-Methyltransferase; Rats	2004
Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology, 2004, Sep-14, Volume: 63, Issue:5 Topics: Antiparkinson Agents; Arteriosclerosis; Catechol O-Methyltransferase; Dementia; Disease Progression; Disease Susceptibility; Homocysteine; Humans; Hyperhomocysteinemia; Inflammation; Levodopa; Models, Biological; Multicenter Studies as Topic; Oxidative Stress; Parkinson Disease; Randomized Controlled Trials as Topic; Substantia Nigra	2004
Is levodopa toxic? Journal of neurology, 2004, Volume: 251 Suppl 6 Topics: Animals; Dose-Response Relationship, Drug; Homocysteine; Humans; Levodopa; Nerve Degeneration; Neurotoxins; Oxidative Stress; Parkinson Disease; Substantia Nigra	2004
Increase in plasma homocysteine levels induced by drug treatments in neurologic patients. Pharmacological research, 2005, Volume: 52, Issue:5 Topics: Cerebrovascular Disorders; Epilepsy; Homocysteine; Humans; Hyperhomocysteinemia; Parkinson Disease; Vitamins	2005
Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses. Current vascular pharmacology, 2006, Volume: 4, Issue:3 Topics: Adolescent; Adult; Animals; Case-Control Studies; Catechol O-Methyltransferase; Cystathionine beta-Synthase; Dopamine Agents; Dystonia; Homocysteine; Humans; Huntington Disease; Hyperhomocysteinemia; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Movement Disorders; Parkinson Disease; Prospective Studies	2006
Homocysteine and Parkinson's disease: a dangerous liaison? Journal of the neurological sciences, 2007, Jun-15, Volume: 257, Issue:1-2 Topics: Brain; Brain Diseases, Metabolic; Causality; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Nerve Degeneration; Parkinson Disease	2007
[Review of the role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric disorders--current evidence and preliminary recommendations]. Fortschritte der Neurologie-Psychiatrie, 2007, Volume: 75, Issue:9 Topics: Aged; Central Nervous System; Child; Dietary Supplements; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Mental Disorders; Nervous System Diseases; Parkinson Disease; Risk Factors; Vitamin B 12; Vitamin B Deficiency	2007
Is the deficiency of vitamin B12 related to oxidative stress and neurotoxicity in Parkinson's patients? CNS & neurological disorders drug targets, 2008, Volume: 7, Issue:1 Topics: Animals; Homocysteine; Humans; Models, Biological; Oxidative Stress; Parkinson Disease; Vitamin B 12 Deficiency	2008
Non-dopaminergic drug treatment of Parkinson's disease. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:4 Topics: Adenosine; Adrenergic alpha-Antagonists; Body Weight; Cholinergic Antagonists; Homocysteine; Humans; Levodopa; Methionine; N-Methylaspartate; Parkinson Disease; Piperidines; Serotonin Receptor Agonists	2001

Trials

21 trial(s) available for homocysteine and Parkinson Disease

Article	Year
Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021, Volume: 88 Topics: Aged; Antiparkinson Agents; Catechols; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Research Design; Vitamin B 12	2021
Parkinson's disease: Research puts spotlight on thiamine deficiency and cardiovascular health. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021, Volume: 93 Topics: Folic Acid; Homocysteine; Humans; Levodopa; Parkinson Disease; Thiamine Deficiency; Vitamin B 12	2021
Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:5 Topics: alpha-Tocopherol; Antioxidants; Antiparkinson Agents; Cognition Disorders; Double-Blind Method; Female; Follow-Up Studies; Homocysteine; Humans; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Predictive Value of Tests; Selegiline; Treatment Outcome; Vitamin B 12	2018
Biochemical and clinical effects of Whey protein supplementation in Parkinson's disease: A pilot study. Journal of the neurological sciences, 2016, Aug-15, Volume: 367 Topics: Amino Acids; Antiparkinson Agents; Brain; Dietary Supplements; Dihydroxyphenylalanine; Double-Blind Method; Female; Follow-Up Studies; Glutathione; Homocysteine; Humans; Male; Middle Aged; Parkinson Disease; Pilot Projects; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Severity of Illness Index; Soybean Proteins; Treatment Outcome; Whey Proteins	2016
Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective? BioMed research international, 2016, Volume: 2016 Topics: Adult; Aged; Aged, 80 and over; Catechol O-Methyltransferase; Catechols; Dopamine Agonists; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Prospective Studies	2016
Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Movement disorders : official journal of the Movement Disorder Society, 2008, Aug-15, Volume: 23, Issue:11 Topics: Aged; Analysis of Variance; Dementia; Double-Blind Method; Female; Homocysteine; Humans; Hyperhomocysteinemia; Male; Mental Status Schedule; Middle Aged; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index	2008
Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients. Parkinsonism & related disorders, 2009, Volume: 15, Issue:6 Topics: Aged; Antiparkinson Agents; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease	2009
Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Movement disorders : official journal of the Movement Disorder Society, 2009, May-15, Volume: 24, Issue:7 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Dementia; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Logistic Models; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Parkinson Disease	2009
Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2009, Jul-15, Volume: 24, Issue:9 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dihydroxyphenylalanine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Statistics as Topic; Time Factors; Tyrosine	2009
Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2010, Feb-15, Volume: 25, Issue:3 Topics: Absorptiometry, Photon; Aged; Analysis of Variance; Anthropometry; Antioxidants; Bone Demineralization, Pathologic; Bone Density; Collagen Type I; Female; Follow-Up Studies; Homocysteine; Humans; Male; Middle Aged; Parkinson Disease; Peptides; Thioctic Acid	2010
Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia. Neuroscience and behavioral physiology, 2010, Volume: 40, Issue:2 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cognition; Cognition Disorders; Dementia; Disability Evaluation; Dyskinesias; Homocysteine; Humans; Levodopa; Memantine; Neuropsychological Tests; Nootropic Agents; Parkinson Disease; Psychiatric Status Rating Scales; Receptors, N-Methyl-D-Aspartate; Treatment Outcome	2010
Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel. Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:9 Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenum; Female; Gels; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease	2011
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. Naunyn-Schmiedeberg's archives of pharmacology, 2011, Volume: 383, Issue:6 Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Combinations; Drug Therapy, Combination; Female; Half-Life; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine	2011
Serum homocysteine and physical exercise in patients with Parkinson's disease. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2011, Volume: 11, Issue:2 Topics: Aged; Antiparkinson Agents; Exercise; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Matched-Pair Analysis; Mental Status Schedule; Middle Aged; Parkinson Disease	2011
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology, 2003, Apr-08, Volume: 60, Issue:7 Topics: Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Pyridoxal Phosphate; Risk Factors; Vitamin B 12; Vitamin B Complex	2003
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:1 Topics: Aged; Antiparkinson Agents; Case-Control Studies; Catechols; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Folic Acid; Homocysteine; Humans; Levodopa; Linear Models; Male; Middle Aged; Nitriles; Parkinson Disease; Vitamin B 12	2005
Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism & related disorders, 2005, Volume: 11, Issue:2 Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Vitamin B 12	2005
Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. European journal of clinical pharmacology, 2006, Volume: 62, Issue:6 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benzophenones; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Prospective Studies; S-Adenosylhomocysteine; Tolcapone	2006
Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. Journal of the neurological sciences, 2006, Oct-25, Volume: 248, Issue:1-2 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cysteine; Female; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Threonine; Time Factors	2006
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology, 2006, Jun-27, Volume: 66, Issue:12 Topics: Aged; Antiparkinson Agents; Canada; Catechols; Double-Blind Method; Drug Combinations; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Placebo Effect; Treatment Outcome; United States; Vitamin B 12; Vitamins	2006
Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurological research, 2006, Volume: 28, Issue:8 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Cognition; Enzyme-Linked Immunosorbent Assay; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Statistics, Nonparametric; Vitamin B 12	2006

Other Studies

104 other study(ies) available for homocysteine and Parkinson Disease

Article	Year
Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease. Journal of the neurological sciences, 2022, Mar-15, Volume: 434 Topics: Cerebral Cortex; Cerebral Cortical Thinning; Homocysteine; Humans; Magnetic Resonance Imaging; Parkinson Disease	2022
Association of elevated blood homocysteine with cognitive decline in early, untreated Parkinson's disease. Journal of the neurological sciences, 2022, Mar-15, Volume: 434 Topics: Cognitive Dysfunction; Disease Progression; Homocysteine; Humans; Parkinson Disease	2022
Severe Hyperhomocysteinemia in a Patient with Parkinson Disease. Clinical chemistry, 2022, 03-04, Volume: 68, Issue:3 Topics: Drug Combinations; Homocysteine; Humans; Hyperhomocysteinemia; Parkinson Disease	2022
Elevation of Plasma Homocysteine and Minor Hallucinations in Parkinson's Disease: A Cross-Sectional Study. Behavioural neurology, 2022, Volume: 2022 Topics: Cross-Sectional Studies; Female; Hallucinations; Homocysteine; Humans; Levodopa; Male; Parkinson Disease	2022
Fiber selectivity of peripheral neuropathy in patients with Parkinson's disease. Acta neurologica Scandinavica, 2022, Volume: 146, Issue:1 Topics: Antiparkinson Agents; Homocysteine; Humans; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases	2022
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients. Cells, 2022, 04-30, Volume: 11, Issue:9 Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Homocysteine; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease	2022
Response to letter: "Association of elevated blood homocysteine with cognitive decline in early, untreated Parkinson's disease". Journal of the neurological sciences, 2022, 07-15, Volume: 438 Topics: Cognitive Dysfunction; Homocysteine; Humans; Neuropsychological Tests; Parkinson Disease	2022
Tolcapone improves outcomes in patients with Parkinson disease treated by levodopa/carbidopa intestinal gel: A pilot study. Medicine, 2022, Aug-12, Volume: 101, Issue:32 Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Drug Combinations; Homocysteine; Humans; Levodopa; Parkinson Disease; Pilot Projects; Quality of Life; Tolcapone	2022
THE CORRELATION BETWEEN SERUM HOMOCYSTEINE LEVEL AND PARKINSON'S DISEASE DISABILITY. Georgian medical news, 2022, Issue:331 Topics: Aged; Brain; Disabled Persons; Homocysteine; Hospitals; Humans; Motor Disorders; Parkinson Disease	2022
Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease. BMC neurology, 2023, Oct-06, Volume: 23, Issue:1 Topics: Aged; Antiparkinson Agents; Benserazide; Homocysteine; Humans; Insulin-Like Growth Factor I; Levodopa; Middle Aged; Parkinson Disease	2023
Subthalamic deep brain stimulation improves vascular endothelial function in Parkinson's disease. Parkinsonism & related disorders, 2023, Volume: 116 Topics: Deep Brain Stimulation; Dyskinesias; Homocysteine; Humans; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome	2023
Correlations between blood lipid, serum cystatin C, and homocysteine levels in patients with Parkinson's disease. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2020, Volume: 20, Issue:2 Topics: Aged; Aged, 80 and over; Case-Control Studies; Cystatin C; Female; Homocysteine; Humans; Levodopa; Lipids; Male; Middle Aged; Parkinson Disease; Risk Factors; Triglycerides	2020
Vascular, inflammatory and metabolic risk factors in relation to dementia in Parkinson's disease patients with type 2 diabetes mellitus. Aging, 2020, 08-15, Volume: 12, Issue:15 Topics: Age Factors; Aged; Biomarkers; Blood Glucose; China; Cholesterol, LDL; Dementia; Diabetes Mellitus, Type 2; Female; Fibrinogen; Homocysteine; Humans; Hyperlipidemias; Inflammation; Male; Middle Aged; Parkinson Disease; Prognosis; Retrospective Studies; Risk Assessment; Risk Factors; Vascular Diseases	2020
Peripheral Neuropathy in Yonsei medical journal, 2020, Volume: 61, Issue:12 Topics: Adult; Aged; Case-Control Studies; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Neural Conduction; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Risk Factors; Uric Acid; Vitamin B 12	2020
Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease. Cell reports, 2021, 03-02, Volume: 34, Issue:9 Topics: Aged; Bacteria; Case-Control Studies; Databases, Genetic; Dysbiosis; Folic Acid; Folic Acid Deficiency; Gastrointestinal Microbiome; Homocysteine; Humans; Hyperhomocysteinemia; Intestines; Male; Metabolome; Metabolomics; Metagenome; Metagenomics; Middle Aged; Mucins; Parkinson Disease; Polysaccharides; Severity of Illness Index	2021
Direct Quantification and Visualization of Homocysteine, Cysteine, and Glutathione in Alzheimer's and Parkinson's Disease Model Tissues. Analytical chemistry, 2021, 07-20, Volume: 93, Issue:28 Topics: Alzheimer Disease; Animals; Cysteine; Fluorescent Dyes; Glutathione; HeLa Cells; Homocysteine; Humans; Mice; Parkinson Disease	2021
Association between homocysteine and third ventricle dilatation, mesencephalic area atrophy in Parkinson's disease with cognitive impairment. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021, Volume: 90 Topics: Aged; Aged, 80 and over; Atrophy; Case-Control Studies; Cognition Disorders; Female; Homocysteine; Humans; Male; Mesencephalon; Middle Aged; Odds Ratio; Parkinson Disease; Risk Factors; Third Ventricle; Ultrasonography, Doppler, Transcranial	2021
Investigating the causality of metabolites involved in one-carbon metabolism with the risk and age at onset of Parkinson's disease: A two-sample mendelian randomization study. Neurobiology of aging, 2021, Volume: 108 Topics: Age of Onset; Dietary Supplements; Disease Susceptibility; Folic Acid; Genome-Wide Association Study; Homocysteine; Mendelian Randomization Analysis; Negative Results; Parkinson Disease; Risk; Vitamin B 12; Vitamin B 6	2021
Serum Klotho, vitamin D, and homocysteine in combination predict the outcomes of Chinese patients with multiple system atrophy. CNS neuroscience & therapeutics, 2017, Volume: 23, Issue:8 Topics: Biomarkers; China; Cross-Sectional Studies; Diagnosis, Differential; Female; Glucuronidase; Homocysteine; Humans; Klotho Proteins; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Prognosis; ROC Curve; Severity of Illness Index; Sex Characteristics; Vitamin D	2017
Serum methylmalonic acid correlates with neuropathic pain in idiopathic Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2017, Volume: 38, Issue:10 Topics: Aged; Antiparkinson Agents; Biomarkers; Cross-Sectional Studies; Female; Homocysteine; Humans; Levodopa; Male; Methylmalonic Acid; Middle Aged; Neural Conduction; Neuralgia; Pain Measurement; Parkinson Disease; Prevalence; Severity of Illness Index; Vitamin B 12	2017
Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinson's Disease: A Preliminary Cross-Sectional Study. Journal of Parkinson's disease, 2017, Volume: 7, Issue:4 Topics: Aged; Catechol O-Methyltransferase; Cognition Disorders; Cross-Sectional Studies; Female; Genotype; Homocysteine; Humans; Levodopa; Male; Methionine; Middle Aged; Neuropsychological Tests; Parkinson Disease; Polymorphism, Single Nucleotide; Polyneuropathies; Statistics, Nonparametric; Vitamins	2017
Homocysteine and cognitive function in Parkinson's disease. Parkinsonism & related disorders, 2017, Volume: 44 Topics: Aged; Antiparkinson Agents; Cognition; Cognitive Dysfunction; Cohort Studies; Female; Homocysteine; Humans; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease	2017
Statement of Concern Regarding: Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a Predictive Factor for Hip Fracture in Elderly Women with Parkinson's Disease. Am J Med. 2005;118:1250-1255. The American journal of medicine, 2018, Volume: 131, Issue:3 Topics: Aged; Female; Hip Fractures; Homocysteine; Humans; Parkinson Disease	2018
The influence of levodopa, entacapone and homocysteine on prevalence of polyneuropathy in patients with Parkinson's disease. Journal of the neurological sciences, 2018, 09-15, Volume: 392 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Polyneuropathies; Statistics, Nonparametric	2018
Clinical utility of SUDOSCAN in predicting autonomic neuropathy in patients with Parkinson's disease. Parkinsonism & related disorders, 2019, Volume: 64 Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Electrophysiology; Female; Galvanic Skin Response; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease	2019
Urate and Homocysteine: Predicting Motor and Cognitive Changes in Newly Diagnosed Parkinson's Disease. Journal of Parkinson's disease, 2019, Volume: 9, Issue:2 Topics: Aged; Case-Control Studies; Cognitive Dysfunction; Disease Progression; Female; Follow-Up Studies; Homocysteine; Humans; Linear Models; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Prognosis; Prospective Studies; Uric Acid	2019
Association of homocysteine, folate, and white matter hyperintensities in Parkinson's patients with different motor phenotypes. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2019, Volume: 40, Issue:9 Topics: Aged; Female; Folic Acid; Gait Disorders, Neurologic; Homocysteine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Postural Balance; Severity of Illness Index; White Matter	2019
[Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa]. Zhonghua yi xue za zhi, 2013, Feb-19, Volume: 93, Issue:7 Topics: Aged; Catechols; Cross-Sectional Studies; Female; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Nitriles; Parkinson Disease	2013
Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:10 Topics: Aged; Antiparkinson Agents; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Logistic Models; Male; Middle Aged; Neural Conduction; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Risk; Vitamin B 12	2013
Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. Parkinsonism & related disorders, 2014, Volume: 20, Issue:1 Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Electromyography; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Vitamin B 12	2014
Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:3 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Atrophy; Brain; Dilatation; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease	2014
Association of seven functional polymorphisms of one-carbon metabolic pathway with total plasma homocysteine levels and susceptibility to Parkinson's disease among South Indians. Neuroscience letters, 2014, May-07, Volume: 568 Topics: Case-Control Studies; Female; Genetic Association Studies; Genetic Predisposition to Disease; Homocysteine; Humans; India; Male; Metabolic Networks and Pathways; Parkinson Disease; Polymorphism, Genetic; Sex Factors	2014
Evaluation of the association between blood homocysteine concentration and the degree of behavioral symptoms in the 6-hydroxydopamine-induced Parkinsonism in rat. Pharmacology, biochemistry, and behavior, 2014, Volume: 124 Topics: Animals; Behavior, Animal; Cell Transplantation; Disease Models, Animal; Homocysteine; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar	2014
Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study. Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:12 Topics: Aged; Antiparkinson Agents; Brachial Artery; Catechols; Dilatation; Endothelium; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Logistic Models; Male; Middle Aged; Nitriles; Parkinson Disease; Statistics, Nonparametric	2014
A coumarin-based fluorescent probe as a central nervous system disease biomarker. Sensors (Basel, Switzerland), 2014, Nov-10, Volume: 14, Issue:11 Topics: Biomarkers; Biosensing Techniques; Coumarins; Fluorescent Dyes; Homocysteine; Humans; Methylmalonic Acid; Parkinson Disease; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence	2014
The expression features of serum Cystatin C and homocysteine of Parkinson's disease with mild cognitive dysfunction. European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:16 Topics: Aged; Cognition Disorders; Cystatin C; Female; Homocysteine; Humans; Male; Middle Aged; Parkinson Disease	2015
Serum levels of homocysteine, asymmetric dimethylarginine and nitric oxide in patients with Parkinson's disease. Acta clinica Belgica, 2016, Volume: 71, Issue:2 Topics: Aged; Arginine; Female; Homocysteine; Humans; Hyperhomocysteinemia; Immunoassay; Male; Middle Aged; Nitric Oxide; Parkinson Disease	2016
The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia. European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:11 Topics: Antiparkinson Agents; Benserazide; Dopamine Agents; Drug Combinations; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Parkinson Disease	2016
Oxidative stress and mitochondrial dysfunction are the underlying events of dopaminergic neurodegeneration in homocysteine rat model of Parkinson's disease. Neurochemistry international, 2016, Volume: 101 Topics: Animals; Antioxidants; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Electron Transport Complex I; Homocysteine; Male; Mitochondria; Oxidative Stress; Parkinson Disease; Rats, Sprague-Dawley	2016
Levodopa, placebo and rotigotine change biomarker levels for oxidative stress. Neurological research, 2017, Volume: 39, Issue:5 Topics: Aged; Analysis of Variance; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dipeptides; Dopamine Agents; Electrochemical Techniques; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Time Factors; Tyrosine	2017
Neuropathy as a potential complication of levodopa use in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2008, Oct-15, Volume: 23, Issue:13 Topics: Analysis of Variance; Antiparkinson Agents; Female; Homocysteine; Humans; Levodopa; Male; Methylmalonic Acid; Parkinson Disease; Peripheral Nervous System Diseases; Retrospective Studies; Vitamin B 12	2008
Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Movement disorders : official journal of the Movement Disorder Society, 2009, Jan-30, Volume: 24, Issue:2 Topics: Aged; Antiparkinson Agents; Cognition; Creatinine; Female; Folic Acid; Genotype; Homocysteine; Humans; Inactivation, Metabolic; Levodopa; Male; Methylation; Methylenetetrahydrofolate Reductase (NADPH2); Motor Skills; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Vitamin B Complex	2009
Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease. Metabolic brain disease, 2009, Volume: 24, Issue:2 Topics: Analysis of Variance; Case-Control Studies; Female; Folic Acid; Folic Acid Deficiency; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Matched-Pair Analysis; Middle Aged; Nerve Degeneration; Parkinson Disease; Reference Values; Statistics, Nonparametric; Vitamin B 12	2009
Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. Movement disorders : official journal of the Movement Disorder Society, 2009, Jul-30, Volume: 24, Issue:10 Topics: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Aged; Aged, 80 and over; Brain; Carbon-Nitrogen Ligases; Case-Control Studies; Cognition Disorders; Cystathionine beta-Synthase; Depression; Female; Folic Acid; Homocysteine; Humans; Immunoassay; Logistic Models; Magnetic Resonance Imaging; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Parkinson Disease; Polymorphism, Genetic; Severity of Illness Index; Vitamin B 12; Vitamin B 6	2009
Peripheral COMT inhibition prevents levodopa associated homocysteine increase. Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Delayed-Action Preparations; Dihydroxyphenylalanine; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors; Tyrosine	2009
Methylation status and neurodegenerative markers in Parkinson disease. Clinical chemistry, 2009, Volume: 55, Issue:10 Topics: Aged; alpha-Synuclein; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Biomarkers; Blood Platelets; Cognition Disorders; Female; Folic Acid; Homocysteine; Humans; Male; Methylation; Middle Aged; Nerve Degeneration; Parkinson Disease; Peptide Fragments; S-Adenosylhomocysteine; S-Adenosylmethionine; Substantia Nigra; Ultrasonography; Vitamin B 6	2009
Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients. Journal of the neurological sciences, 2009, Dec-15, Volume: 287, Issue:1-2 Topics: Age Distribution; Aged; Aged, 80 and over; Amino Acid Substitution; Antiparkinson Agents; Base Sequence; Biomarkers; DNA Mutational Analysis; Female; Gene Frequency; Genetic Markers; Genetic Predisposition to Disease; Genetic Testing; Genotype; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Dehydrogenase (NAD+); Parkinson Disease; Polymorphism, Genetic; Sex Distribution	2009
Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa. Neuroscience letters, 2010, Jan-14, Volume: 468, Issue:3 Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Erythrocytes; Female; Genotype; Homocysteine; Humans; Levodopa; Male; Methylation; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic; S-Adenosylhomocysteine; S-Adenosylmethionine	2010
Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients. European journal of neurology, 2010, Volume: 17, Issue:5 Topics: Aged; Cross-Sectional Studies; Dopamine Agents; Female; Genetic Predisposition to Disease; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Secondary Prevention; Treatment Outcome; Vitamin B 12	2010
L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2010, Volume: 17, Issue:6 Topics: Aged; Antiparkinson Agents; Case-Control Studies; Female; Homocysteine; Humans; Levodopa; Male; Methionine; Middle Aged; Parkinson Disease; Statistics, Nonparametric	2010
Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2010, Volume: 31, Issue:5 Topics: Aged; Antiparkinson Agents; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors	2010
Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2010, Volume: 20, Issue:10 Topics: Antiparkinson Agents; Drug Therapy, Combination; Duodenum; Female; Home Infusion Therapy; Homocysteine; Humans; Infusions, Parenteral; Levodopa; Male; Methyldopa; Parkinson Disease	2010
Elevated levels of methylmalonate and homocysteine in Parkinson's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis. Dementia and geriatric cognitive disorders, 2010, Volume: 29, Issue:6 Topics: Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Case-Control Studies; Female; Folic Acid; Homocysteine; Humans; Male; Matched-Pair Analysis; Methylmalonic Acid; Middle Aged; Parkinson Disease; Reference Values; Supranuclear Palsy, Progressive; Vitamin B 12	2010
Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease. Parkinsonism & related disorders, 2010, Volume: 16, Issue:10 Topics: Antiparkinson Agents; Area Under Curve; Circadian Rhythm; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Vitamins	2010
Depression, Parkinson disease, Alzheimer disease. The homocysteine hypothesis. Neurosciences (Riyadh, Saudi Arabia), 2010, Volume: 15, Issue:3 Topics: Alzheimer Disease; Depression; Homocysteine; Humans; Parkinson Disease	2010
The combination of homocysteine and C-reactive protein predicts the outcomes of Chinese patients with Parkinson's disease and vascular parkinsonism. PloS one, 2011, Apr-27, Volume: 6, Issue:4 Topics: Adult; Aged; C-Reactive Protein; China; Cross-Sectional Studies; Female; Homocysteine; Humans; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Vascular Diseases	2011
Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients. Neuromolecular medicine, 2012, Volume: 14, Issue:1 Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic; Ubiquinone; Vitamin B 12	2012
The impact of MRI white matter hyperintensities on dementia in Parkinson's disease in relation to the homocysteine level and other vascular risk factors. Neuro-degenerative diseases, 2013, Volume: 12, Issue:1 Topics: Aged; Basal Ganglia; Cardiovascular Diseases; Female; Hippocampus; Homocysteine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Fibers; Parkinson Disease; Poland; Risk Factors; Supranuclear Palsy, Progressive; White People	2013
Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease. Pharmacogenetics and genomics, 2012, Volume: 22, Issue:10 Topics: Catechol O-Methyltransferase; Cognition Disorders; Female; Folic Acid; Genetic Association Studies; Genetic Predisposition to Disease; Homocysteine; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Parkinson Disease; Polymorphism, Genetic; Reduced Folate Carrier Protein; Vitamin B 12	2012
Elevated homocysteine by levodopa is detrimental to neurogenesis in parkinsonian model. PloS one, 2012, Volume: 7, Issue:11 Topics: Animals; Blotting, Western; Dopamine Agonists; Flow Cytometry; Homocysteine; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurogenesis; Parkinson Disease; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction	2012
Homocysteine and vitamin B12 levels related to MRI white matter abnormalities in Parkinson's disease dementia. Neuro-degenerative diseases, 2013, Volume: 12, Issue:3 Topics: Basal Ganglia; Female; Hippocampus; Homocysteine; Humans; Male; Nerve Fibers; Parkinson Disease; Supranuclear Palsy, Progressive	2013
Why is homocysteine toxic for the nervous and immune systems? Current aging science, 2013, Volume: 6, Issue:1 Topics: Animals; Brain Ischemia; Carnosine; Female; Homocysteine; Humans; Hyperhomocysteinemia; Neuroimmunomodulation; Neuroprotective Agents; Parkinson Disease; Pregnancy; Rats; Reactive Oxygen Species; Receptors, N-Methyl-D-Aspartate	2013
Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2002, Volume: 109, Issue:12 Topics: Aged; Aged, 80 and over; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Male; Middle Aged; Neopterin; Parkinson Disease; Vitamin B 12	2002
Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Archives of neurology, 2003, Volume: 60, Issue:1 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Coronary Artery Disease; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Vitamin B 12	2003
Will caloric restriction and folate protect against AD and PD? Neurology, 2003, Feb-25, Volume: 60, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Animals; Brain; Brain-Derived Neurotrophic Factor; Caloric Restriction; Disease Models, Animal; Energy Intake; Folic Acid; Homocysteine; Humans; Middle Aged; Neurons; Oxidative Stress; Parkinson Disease; Rats; Risk Factors	2003
Oxidative damage and cytogenic analysis in leukocytes of Parkinson's disease patients. Neurology, 2003, Feb-25, Volume: 60, Issue:4 Topics: Cytogenetic Analysis; Homocysteine; Humans; Inflammation; Interferon-gamma; Leukocytes; Macrophages; Neopterin; Oxidative Stress; Parkinson Disease; T-Lymphocytes; Tryptophan	2003
Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. Journal of the neurological sciences, 2003, Mar-15, Volume: 207, Issue:1-2 Topics: Aged; Analysis of Variance; Carotid Arteries; Female; Homocysteine; Humans; Hypertrophy; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease; Statistics, Nonparametric; Tunica Intima; Ultrasonography	2003
Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta neurologica Scandinavica, 2003, Volume: 108, Issue:1 Topics: Antiparkinson Agents; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Parkinson Disease	2003
High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson's disease patients. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2003, Volume: 36, Issue:10 Topics: Aged; Female; Homocysteine; Humans; Male; Parkinson Disease; Riboflavin; Riboflavin Deficiency; Treatment Outcome	2003
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology, 2004, Feb-24, Volume: 62, Issue:4 Topics: Antiparkinson Agents; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Methylation; Parkinson Disease; S-Adenosylmethionine; Vitamin B Complex	2004
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology, 2004, Feb-24, Volume: 62, Issue:4 Topics: Antiparkinson Agents; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Neopterin; Parkinson Disease; Vitamin B Complex	2004
Levodopa elevates homocysteine: is this a problem? Archives of neurology, 2004, Volume: 61, Issue:5 Topics: Antiparkinson Agents; Brain; Homocysteine; Humans; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases; S-Adenosylmethionine	2004
Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Archives of neurology, 2004, Volume: 61, Issue:5 Topics: Action Potentials; Aged; Antiparkinson Agents; Axons; Chromatography, High Pressure Liquid; Electrophysiology; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nerve Degeneration; Neural Conduction; Parkinson Disease; Sural Nerve	2004
Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Archives of neurology, 2004, Volume: 61, Issue:6 Topics: Aged; Cognition Disorders; Depression; Female; Homocysteine; Humans; Male; Middle Aged; Mood Disorders; Motor Skills Disorders; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales	2004
Folate intake and risk of Parkinson's disease. American journal of epidemiology, 2004, Aug-15, Volume: 160, Issue:4 Topics: Adult; Cohort Studies; Diet; Female; Folic Acid; Follow-Up Studies; Homocysteine; Humans; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Prospective Studies; Reference Values; Risk Factors; United States; Vitamin B 12; Vitamin B 6	2004
Coffee: for most, it's safe. Coffee has been blamed for everything from moral turpitude to cancer. But none of the bad raps have stuck. Coffee may even be good for you. Harvard women's health watch, 2004, Volume: 12, Issue:1 Topics: Caffeine; Cardiovascular System; Coffee; Diabetes Mellitus, Type 2; Female; Homocysteine; Humans; Liver Diseases; Neoplasms; Osteoporosis; Parkinson Disease; Pregnancy	2004
Studies on homocysteine and dehydroepiandrosterone sulphate plasma levels in Alzheimer's disease patients and in Parkinson's disease patients. Neurotoxicity research, 2004, Volume: 6, Issue:4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dehydroepiandrosterone Sulfate; Female; Homocysteine; Humans; Male; Middle Aged; Parkinson Disease	2004
Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. European journal of neurology, 2005, Volume: 12, Issue:5 Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Parkinson Disease; Vitamin B 12	2005
Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism & related disorders, 2005, Volume: 11, Issue:4 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Sectional Studies; Drug Therapy, Combination; Enzyme Inhibitors; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Vitamin B 12	2005
Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life sciences, 2005, Aug-26, Volume: 77, Issue:15 Topics: Aged; Alzheimer Disease; Chromatography, High Pressure Liquid; Female; Homocysteine; Humans; Male; Middle Aged; Parkinson Disease	2005
Endothelial function markers in parkinsonian patients with hyperhomocysteinemia. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2005, Volume: 12, Issue:6 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biomarkers; Case-Control Studies; E-Selectin; Endothelium, Vascular; Fasting; Female; Homocysteine; Humans; Hyperhomocysteinemia; Intercellular Adhesion Molecule-1; Levodopa; Male; Middle Aged; Nitric Oxide; Parkinson Disease; Superoxide Dismutase	2005
Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clinical chemistry and laboratory medicine, 2005, Volume: 43, Issue:10 Topics: Aged; Case-Control Studies; Cognition Disorders; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease	2005
RETRACTED: Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. The American journal of medicine, 2005, Volume: 118, Issue:11 Topics: Accidental Falls; Aged; Antiparkinson Agents; Cohort Studies; Female; Follow-Up Studies; Fractures, Spontaneous; Hip Fractures; Homocysteine; Humans; Hyperhomocysteinemia; Immobilization; Incidence; Japan; Levodopa; Osteoporosis; Parkinson Disease; Proportional Hazards Models; Risk Factors	2005
Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology, 2005, Nov-08, Volume: 65, Issue:9 Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Amyloid beta-Peptides; Brain; Causality; Cerebral Amyloid Angiopathy; Cognition Disorders; Creatinine; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Memory Disorders; Middle Aged; Neurodegenerative Diseases; Parkinson Disease; Predictive Value of Tests; Vitamin B 12	2005
Clinical course in Parkinson's disease with elevated homocysteine. Parkinsonism & related disorders, 2006, Volume: 12, Issue:2 Topics: Affect; Aged; Aged, 80 and over; Biomarkers; Cognition; Cohort Studies; Disease Progression; Female; Homocysteine; Humans; Male; Middle Aged; Movement; Neuropsychological Tests; Parkinson Disease; Risk Factors; Vitamin B Complex; Vitamins	2006
Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias. Clinical chemistry and laboratory medicine, 2006, Volume: 44, Issue:7 Topics: Cross-Sectional Studies; Dyskinesias; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease	2006
Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neuroscience letters, 2006, Aug-14, Volume: 404, Issue:1-2 Topics: Adult; Aged; Aged, 80 and over; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Reference Values; Vitamin B 12	2006
Neurotoxicity of levodopa: treatment-associated homocysteine increase. Nature clinical practice. Neurology, 2007, Volume: 3, Issue:6 Topics: Animals; Antiparkinson Agents; Homocysteine; Humans; Levodopa; Parkinson Disease	2007
Homocysteine in restless legs syndrome. Sleep medicine, 2008, Volume: 9, Issue:4 Topics: Aged; Antiparkinson Agents; Catechols; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Reference Values; Restless Legs Syndrome; Vitamin B 12; Vitamin B 6	2008
Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. Neuromolecular medicine, 2007, Volume: 9, Issue:3 Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic; Vitamin B 12	2007
5,10-methylenetetrahydrofolate reductase C677T gene polymorphism can influence age at onset of Parkinson's disease. Acta neurologica Taiwanica, 2007, Volume: 16, Issue:3 Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Female; Genetic Predisposition to Disease; Genotype; Homocysteine; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic	2007
Prospective study of dietary pattern and risk of Parkinson disease. The American journal of clinical nutrition, 2007, Volume: 86, Issue:5 Topics: Adult; Aged; Diet; Female; Homocysteine; Humans; Male; Middle Aged; Parkinson Disease; Prospective Studies; Risk Factors	2007
Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology, 1995,Fall, Volume: 16, Issue:3 Topics: Aged; Cysteine; Homocysteine; Humans; Middle Aged; Parkinson Disease; Sulfates	1995
The thermolabile variant of 5,10-methylenetetrahydrofolate reductase is not associated with Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 1997, Volume: 62, Issue:6 Topics: 5,10-Methylenetetrahydrofolate Reductase (FADH2); Folic Acid; Genotype; Homocysteine; Homozygote; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Oxidoreductases; Parkinson Disease	1997
Elevated plasma levels of homocysteine in Parkinson's disease. European neurology, 1998, Volume: 40, Issue:4 Topics: Aged; Aged, 80 and over; Case-Control Studies; Cysteine; Dipeptides; Female; Homocysteine; Humans; Male; Middle Aged; Parkinson Disease; Risk Factors	1998
Hyperhomocysteinaemia in Parkinson's disease. Journal of neurology, 1998, Volume: 245, Issue:12 Topics: Aged; Case-Control Studies; Female; Homocysteine; Humans; Male; Middle Aged; Parkinson Disease	1998
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet (London, England), 1999, Jul-10, Volume: 354, Issue:9173 Topics: Aged; Antiparkinson Agents; Carboxy-Lyases; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substantia Nigra; Vascular Diseases	1999
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology, 2000, Aug-08, Volume: 55, Issue:3 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cysteine; Female; Folic Acid; Genotype; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease; Point Mutation	2000
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology, 2001, Jan-23, Volume: 56, Issue:2 Topics: Genotype; Homocysteine; Humans; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease	2001
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology, 2001, Jan-23, Volume: 56, Issue:2 Topics: Genotype; Homocysteine; Humans; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease	2001
Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. Clinical chemistry, 2001, Volume: 47, Issue:6 Topics: Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine	2001
Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neuroscience letters, 2001, Jul-27, Volume: 308, Issue:1 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Cardiovascular Diseases; Dopa Decarboxylase; Down-Regulation; Drug Interactions; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Methionine; Middle Aged; Parkinson Disease; S-Adenosylmethionine; Up-Regulation	2001
Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. Journal of neurochemistry, 2002, Volume: 80, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Brain; Cell Survival; Corpus Striatum; Diet; Dopamine; Drug Synergism; Folic Acid Deficiency; Homocysteine; Humans; Hyperhomocysteinemia; Iron; Male; Mice; Mice, Inbred C57BL; Mitochondria; Motor Activity; Neurons; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Rotenone; Tumor Cells, Cultured	2002
3-OMD and homocysteine plasma levels in parkinsonian patients. Journal of neural transmission (Vienna, Austria : 1996), 2002, Volume: 109, Issue:2 Topics: Dihydroxyphenylalanine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine	2002